A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase III, multi-Center, randomized, placebo-controlled trial to investigate the
efficacy and safety of CS1001 in combination with Oxaliplatin and Capecitabine (XELOX)
chemotherapy in first-line subjects with unresectable locally advanced or metastatic gastric
adenocarcinoma (GC) or gastro-esophageal junction (GEJ) adenocarcinoma.